Author of the publication

copy delete add this publication to your clipboard
community post
history of this post
URL
DOI
BibTeX
EndNote
APA
Chicago
DIN 1505
Harvard
MSOffice XML

A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G

R. Stork, D. Müller, and R. Kontermann. Protein Engineering, Design and Selection, 20 (11): 569--576 (2007)
DOI: 10.1093/protein/gzm061

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Univ. -Prof. Dr. Roland Kontermann University of Stuttgart

E. Garrelts

E. Zafeiriou

Roland Weil University of Stuttgart

apl. Prof. Dr. Roland Gehrke University of Stuttgart

Other publications of authors with the same name

Systemic network analysis identifies XIAP and I kappa B alpha as potential drug targets in TRAIL resistant BRAF mutated melanomaG. Del Mistro, P. Lucarelli, I. Müller, S. De Landtsheer, A. Zinoveva, M. Hutt, M. Siegemund, R. Kontermann, S. Beissert, T. Sauter and 1 other author(s). NPJ systems biology and applications, (2018)Superior Properties of Fc-comprising scTRAIL Fusion ProteinsM. Hutt, L. Marquardt, O. Seifert, M. Siegemund, I. Müller, D. Kulms, K. Pfizenmaier, and R. Kontermann. Molecular cancer therapeutics, 16 (12): 2792-2802 (2017)Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer CellsV. Massafra, S. Tundo, A. Dietzig, A. Ducret, C. Jost, C. Klein, R. Kontermann, H. Knoetgen, M. Steegmaier, A. Romagnani and 1 other author(s). The journal of immunology, 209 (2): 493-504 (2021)Viro-antibody therapy : engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeuticsR. Kontermann, G. Ungerechts, and D. Nettelbeck. mAbs, 13 (1): 1982447 (2021)The making of bispecific antibodiesU. Brinkmann, and R. Kontermann. mAbs, 9 (2): 182-212 (2017)A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cellsN. Aschmoneit, S. Steinlein, L. Kühl, O. Seifert, and R. Kontermann. Scientific reports, (2021)Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain formatS. Fellermeier, N. Beha, J. Meyer, S. Ring, S. Bader, R. Kontermann, and D. Müller. OncoImmunology, 5 (11): e1238540 (2016)Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneouslyF. Tansi, R. Rüger, C. Böhm, F. Steiniger, R. Kontermann, U. Teichgraeber, A. Fahr, and I. Hilger. Acta biomaterialia, (2017)Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IVL. Schmitt, A. Rau, O. Seifert, J. Honer, M. Hutt, S. Schmid, J. Zantow, M. Hust, S. Dübel, M. Olayioye and 1 other author(s). mAbs, 9 (5): 831-843 (2017)Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNFK. Liang, J. Roels, M. Lavaert, T. Putteman, L. Boehme, L. Tilleman, I. Velghe, V. Pegoretti, I. Walle, S. Sontag and 12 other author(s). Nature immunology, 24 (3): 474-486 (2023)

PUMA

Disambiguation of "Kontermann, Roland E."